Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe
暂无分享,去创建一个
D. Hatsukami | R. Tyndale | C. Dorr | Kristine L. Rhodes | P. Jacobson | Ellen Meier | D. Carroll | Carol Hernandez | Greg Braaten | L. Frizzell | S. Murphy | Casey R Dorr | Sharon E Murphy
[1] Ashley B Cole,et al. Racial/ethnic group comparisons of quit ratios and prevalences of cessation-related factors among adults who smoke with a quit attempt , 2021, The American journal of drug and alcohol abuse.
[2] J. Prochaska,et al. Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes. , 2021, Experimental and clinical psychopharmacology.
[3] A. Begnaud,et al. Recommendations to researchers for aiding in increasing American Indian representation in genetic research and personalized medicine , 2020, Personalized medicine.
[4] Elizabeth A. Scoville,et al. Precision nicotine metabolism-informed care for smoking cessation in Crohn’s disease: A pilot study , 2020, PloS one.
[5] P. Spicer,et al. An Alaska Native community’s views on genetic research, testing, and return of results: Results from a public deliberation , 2020, PloS one.
[6] C. Lerman,et al. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions , 2020, Cancer Prevention Research.
[7] F. J. McClernon,et al. Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers , 2020, Cancer Epidemiology, Biomarkers & Prevention.
[8] Nicole Senft,et al. Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study , 2019, Cancer Epidemiology, Biomarkers & Prevention.
[9] D. Thompson,et al. The relationship between nicotine metabolism and nicotine and carcinogen exposure among American Indian commercial cigarette smokers and electronic nicotine delivery system users. , 2019, Addictive behaviors.
[10] Elizabeth A. Scoville,et al. Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT , 2018, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[11] B. Howard,et al. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer , 2017, Pharmacogenetics and genomics.
[12] L. Hawk,et al. Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking , 2016, Pharmacology Biochemistry and Behavior.
[13] D. Erickson,et al. Cigarette Smoking Among Urban American Indian Adults - Hennepin and Ramsey Counties, Minnesota, 2011. , 2016, MMWR. Morbidity and mortality weekly report.
[14] L. Le Marchand,et al. Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity. , 2016, Carcinogenesis.
[15] C. Lerman,et al. Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio , 2016, Journal of Neuroimmune Pharmacology.
[16] L. Hawk,et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. , 2015, The Lancet. Respiratory medicine.
[17] B. Lushniak,et al. The Health consequences of smoking—50 years of progress : a report of the Surgeon General , 2014 .
[18] L. Hawk,et al. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race , 2014, Psychopharmacology.
[19] A. Mainous,et al. Racial Differences in Attitudes toward Personalized Medicine , 2013, Public Health Genomics.
[20] N. Benowitz,et al. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. , 2013, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[21] D. Hatsukami,et al. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. , 2013, Carcinogenesis.
[22] Beth A. Glenn,et al. Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study. , 2012, Ethnicity & disease.
[23] D. Heitjan,et al. Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[24] K. Fagerström. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[25] M. Spitz,et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. , 2011, Journal of the National Cancer Institute.
[26] H. McRobbie,et al. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence , 2011, Psychopharmacology.
[27] Robyn L Sterling. Genetic research among the Havasupai--a cautionary tale. , 2011, The virtual mentor : VM.
[28] C. Lerman,et al. Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[29] C. Jepson,et al. Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended‐Duration Transdermal Nicotine Therapy , 2010, Clinical pharmacology and therapeutics.
[30] N. Benowitz,et al. Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African‐American Light Smokers , 2009, Clinical pharmacology and therapeutics.
[31] C. Lerman,et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study , 2009, Pharmacology Biochemistry and Behavior.
[32] L. Epstein,et al. Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo‐controlled Trial of Bupropion , 2008, Clinical pharmacology and therapeutics.
[33] P. Villalta,et al. Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[34] N. Benowitz,et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior , 2006, Clinical pharmacology and therapeutics.
[35] C. Lerman,et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation , 2006, Clinical pharmacology and therapeutics.
[36] N. Benowitz,et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.
[37] C. Pomerleau,et al. Nicotine metabolite ratio as a predictor of cigarette consumption. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[38] R. Tyndale,et al. Nicotine metabolism defect reduces smoking , 1998, Nature.
[39] L. Kozlowski,et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.
[40] R C Frecker,et al. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. , 1989, British journal of addiction.